Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vysis PathVysion HER-2 Kit Labeling: Herceptin Exclusion Endorsed By Panel

This article was originally published in The Gray Sheet

Executive Summary

Labeling for Vysis' PathVysion HER-2 DNA probe kit should state that results from the test are intended for use as a rapid assessment of the potential response to Adriamycin therapy, FDA's Immunology Devices panel concluded at a Nov. 9 meeting.

You may also be interested in...

Vysis' PathVysion Could Join Dako Diagnostic On Herceptin Labeling

Vysis plans to submit a premarket approval application supplement to the Center for Devices and Radiological Health to add Genentech's Herceptin (trastuzumab) chemotherapy agent to the labeling of the PathVysion HER-2/neu gene amplification assay.

ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts